Business · 15/06/2012
FDA Clears PARAPLATIN and SUSTIVA for Continued Sale
The FDA has ruled that the two medications, Carboplatin injection and Efavirenz capsules, will not be removed from the market due to safety or effectiveness concerns, allowing the agency to continue approving new applications for these products.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →